# Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease

> **NCT02596997** · — · NO_LONGER_AVAILABLE · sponsor: **Jazz Pharmaceuticals**

## Conditions studied

- Adenovirus

## Interventions

- **DRUG:** Brincidofovir

## Key facts

- **NCT ID:** NCT02596997
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2022-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02596997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02596997, "Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02596997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*